Skip to main content
Fig. 2 | Journal of Ovarian Research

Fig. 2

From: Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

Fig. 2

Evaluation of drug combinations in cell growth assays. The indicated cells were treated with combinations of carboplatin and the indicated BH3 mimetic. After 72 h, the surviving cell number was estimated by staining with SRB. Combination indices (mean ± S.D., n = 3) at fraction affected = 0.5 were significantly different from CI = 1.0 where indicated (paired t-test, *P ≤ 0.05 and **P ≤ 0.01.)

Back to article page